The Journal of Infectious Diseases · 2003 · 83 citations · 40 references
PharmacyImmunologyPharmacotherapyAutoimmunityClinical ImmunologyImmunology Of Infectious DiseasesAntiretroviral TherapyAntiviral AgentsAntiviral Drug ResistanceAntiviral PharmacotherapyAntiviral TherapyTreatment DurationAntiretroviral ToxicityC-reactive Protein TestingCd8 Positive T Cell ResponsesCd8 Positive T CellsHepatic Toxicity Of AntiretroviralsHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyLong-acting Antiretroviral Therapy
We evaluated the effect of long-cycle structured intermittent therapy (SIT; 4 weeks without highly active antiretroviral therapy [HAART] followed by 8 weeks with HAART) versus continuous HAART. The study was prematurely terminated to new enrollment because of the emergence of genetic mutations associated with resistance to antiretroviral drugs in 5 patients. After 48 weeks, there was no significant difference between groups in lipid, hepatic transaminase, and C-reactive protein levels in 41 patients. Although there were no differences in CD4(+) or CD8(+) T cell counts or the percentage of cells that were CD4(+)CD25(+), CD8(+)CD25(+), or CD4(+)DR(+), patients who received SIT had a significantly higher percentage of CD8(+)CD38(+) and CD8(+)DR(+) cells. There was no clear autoimmunization effect by immunologic or virologic parameters. There was no benefit to long-cycle SIT versus continuous HAART with regard to certain toxicity, immunologic, or virologic parameters.
40
Immune control of HIV-1 after early treatment of acute infection
Eric Rosenberg, Marcus Altfeld, Samuel Poon et al. · Nature · 2000 · 998 citations